Nio Turns in Larger Loss than Expected, Plans for Growing Future

Tuesday, March 2, 2021 | Steve Anderson
Nio Turns in Larger Loss than Expected, Plans for Growing Future

Nio (NYSE:NIO) recently turned in its fourth-quarter earnings figures and revealed that there's some softness in the electric car market after all. Its fourth-quarter earnings report turned in a loss that was bigger than consensus expectations were looking for, and worse yet, the next quarter isn't looking all that great either. But Nio isn't taking these developments lying down, and is already preparing for better days to come.

A Short-Circuited Quarter

Nio's fourth quarter did not turn out as most had hoped. The company posted a loss of 1.49 billion yuan—about $230.27 million US as of this writing—against an expected loss of 757 million yuan, about $116.99 million US. Regardless of the currency conversion, though, that's still a loss of around double what was expected, and that's a bad quarter by any measure.

Back in April of last year, when the pandemic was just getting started worldwide but had already hit China hard, the Chinese government threw an extra $1 billion in funding behind Nio, a move that helped the company stabilize and address issues of declining sales and recalls in progress. The company reported, as part of its fourth-quarter operations, that it had delivered 7,225 vehicles in January, and another 5,578 in February. All fine and well until you look at some of Nio's competitors, like Tesla (NASDAQ:TSLA), who delivered a grand total of 180,570 vehicles for its fourth quarter, or a little better than 14 times what Nio did.

Worse yet, the short-term future for Nio isn't looking that bright. CEO William Li, on an analyst call, noted that the company was planning to be “more conservative” in its estimates, but suggested that the second half of 2021 might improve. In fact, Li noted, the company was “quite confident” about the demand for the latter half of 2021, but the company didn't have “the full visibility” yet. Still, the company hopes to deliver between 20,000 and 25,000 in the first quarter, up substantially from the previous quarter's figures.

Million-Candlepower Bullish Sentiment

Our latest research on Nio will likely surprise many out there, as sentiment has been trending increasingly bullish for the last six months. In fact, with the latest figures, Nio officially slipped into a consensus “buy”, where it had been languishing as a “hold” since six months ago.

Six months ago, the company had two “sell” ratings, six “hold” and three “buy” to its credit. Three months ago, that improved to just one “sell”, five “hold” and six “buy.” A month ago, further improvement came in with one “sell, “ seven “hold” and nine “buy.” Now, the company's ratings have officially crossed the Rubicon to “buy”, with no “sell” ratings, seven “hold” and nine “buy”.

The price target has also been steadily increasing in that time; six months ago, the company was down around $11.38 for a price target. That increased three months ago to $28.69, and then a month ago, increased again to $46.48. Now, it currently sits at $50.64, and given the company currently trades at $46.02, there may yet be some room to grow in the future.

The Future is a Moving Target

Nio is existing in a strange space right now. Its stock is through the roof but its performance is a disaster. Its lunch has been eaten by a string of competitors so far, and trying to compare Nio's figures to Tesla's is like comparing Lipton Brisk sales to a kid's lemonade stand. However, Nio has an eye on future expansion, which is certainly better news than we got out of this quarter. Nio has plans to push into Europe this year, and already has talks in mind to get in on the United States market, though those are at a much earlier stage than the European expansion. With Tesla pretty much the big name in the US market, and a slew of US carmakers looking to land their slice of the electric vehicle market, the contributions to Nio's bottom line from the US market aren't likely to be big. Any extra sales, however, are extra sales, and as long as they're not particularly expensive, are worth pursuing accordingly.

Nio, like the rest of the electric car market, is also facing some troubles from the worldwide semiconductor shortage. A shortage in batteries isn't exactly helping matters either, and the ongoing issues in lithium and other rare earth minerals is likewise an impediment. But these are impediments that hurt the entire market, not just Nio specifically.

So despite the fact that Nio took a serious hit with its fourth-quarter figures, and is likely to be limping along for at least another quarter, Nio has an excellent potential to do well in the Asian electric car market. That should give it quite a bit of edge going forward, and provide reason for the confidence placed in Nio by the latest analyst figures. Those who already have Nio shares, keep them because a new leg upward might be in store for the second half of 2020.

Featured Article: What are popular green investing opportunities?

7 Healthcare Stocks Delivering Innovation in 2021

We all knew that traditional healthcare services were disrupted in 2020. The patient-doctor relationship went virtual. In the early months of the pandemic, many people in need of elective surgeries simply did not have that option available to them. And even local pharmacies took on a new e-commerce role as curbside pickup or home delivery of prescription medication became the norm.

Not surprisingly healthcare stocks were battered last year. Overall, the sector was down 11%, far below the S&P 500 Index that climbed over 15%.

However, the market is always forward-looking with a particular eye towards innovation. The healthcare sector has many companies that are developing innovative approaches in areas such as gene editing. And other companies are in late-stage trials for drugs that can deliver breakthrough results for conditions that continue to plague our world.

That’s the focus of this presentation. We’ve identified 7 healthcare stocks that are delivering innovative ideas that will help deliver better patient outcomes. And in some cases will revolutionize medicine altogether. These are also the stocks that analysts have their eye on.

View the "7 Healthcare Stocks Delivering Innovation in 2021".

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
NIO (NIO)1.6$38.09+2.6%N/A-40.96Buy$49.94
Tesla (TSLA)1.4$754.14+7.4%N/A1,514.34Hold$370.59
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.